HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 5 of 5
Allo CD7 CAR WU-CART-007
The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”).
Carfilzomib in ALL
This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen.
Humanized CART19 Phase 2 Trial
This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Ribociclib With Everolimus And Dexamethasone For Relapsed ALL
CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen.
T2017-002 TACL Ixazomib Study
CHOP and the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium is conducting a study for children and young adults 21 years old or younger who have relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.